ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (HKG:1541)
Hong Kong · Delayed Price · Currency is HKD
9.79
-0.21 (-2.10%)
Jul 16, 2025, 4:08 PM HKT
HKG:1541 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
FY 2024 | FY 2023 | FY 2022 | FY 2021 |
---|
Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
---|
| 74.15 | 0.39 | 0.54 | 5.07 |
| 5.39 | 7.31 | 5.15 | 8.74 |
| 79.54 | 7.7 | 5.69 | 13.81 |
| 933.61% | 35.24% | -58.79% | - |
| 79.54 | 7.7 | 5.69 | 13.81 |
| 64.82 | 80.42 | 92.8 | 48.32 |
| 322.76 | 291.94 | 277.35 | 175.95 |
| 387.58 | 372.37 | 370.14 | 224.27 |
| -308.04 | -364.67 | -364.45 | -210.47 |
| -3.45 | -1.52 | -0.79 | -0.89 |
Interest & Investment Income | 6.38 | 10.8 | 9.51 | 1.64 |
Currency Exchange Gain (Loss) | 1.79 | 0.1 | 26.11 | -9.13 |
Other Non Operating Income (Expenses) | -0.02 | -25.92 | -73.27 | -514.83 |
EBT Excluding Unusual Items | -303.34 | -381.22 | -402.89 | -733.67 |
Gain (Loss) on Sale of Investments | 14.15 | 1.76 | - | - |
Gain (Loss) on Sale of Assets | - | - | - | 0.56 |
| -27.4 | - | - | - |
| - | - | - | 0.17 |
| -316.59 | -379.46 | -402.89 | -732.95 |
Earnings From Continuing Operations | -316.59 | -379.46 | -402.89 | -732.95 |
Minority Interest in Earnings | 0.74 | - | - | - |
| -315.86 | -379.46 | -402.89 | -732.95 |
| -315.86 | -379.46 | -402.89 | -732.95 |
Shares Outstanding (Basic) | 377 | 362 | 332 | 86 |
Shares Outstanding (Diluted) | 377 | 362 | 332 | 86 |
| 4.24% | 9.05% | 284.99% | - |
| -0.84 | -1.05 | -1.21 | -8.50 |
| -0.84 | -1.05 | -1.21 | -8.50 |
| -138.44 | -370.25 | -261.93 | -231.24 |
| -0.37 | -1.02 | -0.79 | -2.68 |
| 100.00% | 100.00% | 100.00% | 100.00% |
| -387.30% | -4739.09% | -6405.13% | -1524.23% |
| -397.12% | -4931.24% | -7080.74% | -5308.15% |
| -174.06% | -4811.50% | -4603.41% | -1674.69% |
| -297.77 | -352.26 | -352.54 | -202.69 |
| 10.28 | 12.41 | 11.91 | 7.77 |
| -308.04 | -364.67 | -364.45 | -210.47 |
Source: S&P Global Market Intelligence. Standard template.
Financial Sources.